Russian Federation: New Registration Rules And Calculation Methodology For Maximum Manufacturer's Sale Prices For Vital And Essential Drugs

Last Updated: 9 October 2015
Article by Anna McDonald

On October 1, 2015, the new versions of the following regulations will come into legal force and effect:

  • The Rules for the state registration and re-registration of maximum sale prices set by pharmaceutical manufacturers for medicines on the list of vital and essential drugs ("EDL") (the EDL Price Registration Rules); and
  • The Methodology for calculating maximum sale prices set by pharmaceutical manufacturers for medicines on the list of vital and essential drugs (the EDL Price Сalculation Methodology).

These new versions of the EDL Price Registration Rules and EDL Price Calculation Methodology were approved by the RF Government Decree No. 979 of September 15, 2015 (the Decree 979).

Decree 979 also clarifies the procedure for the maintenance of the state register of maximum manufacturers' sale prices for medicines (the EDL Price Register).

Decree 979 introduces a large number of changes that are nonetheless mainly supplementary in nature. The new versions of the EDL Price Registration Rules and EDL Price Calculation Methodology detail and formalize many issues concerning calculations of the maximum manufacturer's sale price for an EDL drug (the Maximum Price) and the grounds for changing it. 

Integration of the Eurasian Economic Community (the EAEC) is reflected in the EDL Price Calculation Methodology by setting out special provisions applicable to manufacturers from EAEC states. Some of the rules contain specific provisions applicable to pharmaceutical manufacturers whose products fall within a specific price segment or to manufacturers intending to package medicines in the Russian Federation, etc. 

Acording to the new EDL Price Registration Rules, in order to register or re-register a Maximum Price for a medicine which is on the EDL (the EDL Drug) an applicant will have to provide more information than previously was required. For example, it will be necessary, inter alia, to provide information about the volumes and manufacturer's sale/import price of the EDL Drug in question and a justification for and calculations of the Maximum Price.

The amount of information needed to register the Maximum Price for an EDL Drug that have not yet entered into the Russian market has been considerably expanded. Manufacturers from EAEC member states will be required to provide information about the entity's accounting policy, a breakdown of expenses and costs, documentation of amounts of certain types of expenses, etc. Foreign manufacturers will be required to provide data supporting information about the foreign manufacturer's minimum sale price for such EDL Drug.

A manufacturer from any EAEC member state planning to package an EDL Drug in the Russian Federation, as well as a holder of a marketing authorization for an EDL Drug will be required to submit a similar set of information if there is no registered Maximum Price of the foreign manufacturer for that medicine. 

A number of limits have been set for Maximum Prices. For example, if an application is being filed to register a Maximum Price within the three years from the date the Maximum Price for the same Medicine has been excluded from the EDL Price Register on the basis of an application from the same marketing authorization holder, the new Maximum Price applied for cannot be more than the price previously excluded. The Maximum Price of a generic1 EDL Drug that is not in circulation cannot exceed 80% of the Maximum Price of the reference drug or its analog. The threshold for a biosimilar2 drug is 90%. Limits on the Maximum Price are set for the second and subsequent foreign manufactured generic/biosimilar drugs (5% lower than the most recent registered Maximum Price for the similar drug), and also for cases of a significant decrease from the maximum registered Maximum Price for reference/similar drugs.

In addition, the new version of the EDL Price Registration Rules sets forth in much greater detail the grounds for re-registration of a Maximum Price. Among the reasons for re-registering a Maximum Price are change in prices for raw materials and supplies and overhead expenses, currency exchange rate fluctuations (for a foreign manufacturer's medicines), however, those are taken into account only if certain additional parameters are observed. The grounds for re-registration of Maximum Prices for EDL Drugs in the lower and average price segment of up to and including 500 rubles are set out separately.

A number of amplifying rules are also introduced to the EDL Price Calculation Methodology. The algorithm for recalculating prices for EDL Drugs of the lower and average price segment of up to 500 rubles is set out in detail. Potential limits on the Maximum Price are clarified, for example, for medicines manufactured within an EAEC member state the price cannot be more than the minimum manufacturer's sale price in the countries for which the information about minimum manufacturer's sale prices for medicines (including customs duties and costs) is being provided.

At the same time, the list of those countries has changed. The "manufacturer's country" continues to be indicated in the list, but the vague wording "other countries" has been removed, Germany was deleted from the list, but Hungary was added.

Attention of manufacturers from EAEC member states planning to do primary and/or secondary packaging of Medicines in the Russian Federation is drawn to the fact that the Maximum Price proposed for registration cannot exceed the maximum registered foreign manufacturer's maximum sale price for that medicine. Furthermore, when calculating the Maximum Price for a different quantity of EDL Drug in the secondary (consumer) packaging, the price for a single pharmaceutical unit cannot increase.

The new version of the EDL Price Calculation Methodology generally corresponds to, and is largely consistent with, the new version of the EDL Price Registration Rules.

Manufacturers and developers of essential medicines should take into account that, according to the statements of the governmental officials3, the new versions of the EDL Price Registration Rules and EDL Price Calculation Methodology are only the first stage in making changes to EDL pricing regulation, and other amendments are expected to be adopted by 2016.


1 a medicine that has the same quality and quantity of active ingredients in the same pharmaceutical form as the reference drug and the bioequivalence or therapeutic equivalence of which to the reference drug has been confirmed by the relevant trials. Federal Law No. 61-FZ on the Circulation of Medicines of April 12, 2010.

2 a biological medicine similar in terms of quality, efficacy and safety parameters to the reference biological medicine in the same pharmaceutical form and having an identical mode of administration. Ibid.

3 Interview with Timofey Nizhegorodtsev, Head of the Department for the Protection of Competition in the Social Sphere and Trade of the Federal Antimonopoly Service of Russia - in Russian

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Webinar, Washington, United States

Join Dentons government contracts lawyers for a Public Contracting Institute (PCI) webinar series involving the most current industry analysis in government contract cost accounting from a team of leaders in the field with unparalleled experience

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.